Order Article Reprints

Lazana I, Papathanassiou M, Konstantellos I, Tzenou T, Kopsaftopoulou A, Liga M, Violaki V, Kyriazopoulou L, Gkirkas K, Papalexandri A, et al. The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry. Cancers. 2025; 17(4):667. https://doi.org/10.3390/cancers17040667

Lazana, Ioanna, Maria Papathanassiou, Ioannis Konstantellos, Tatiana Tzenou, Anastasia Kopsaftopoulou, Maria Liga, Vasiliki Violaki, Lydia Kyriazopoulou, Konstantinos Gkirkas, Apostolia Papalexandri, and et al. 2025. "The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry" Cancers 17, no. 4: 667. https://doi.org/10.3390/cancers17040667

Lazana, I., Papathanassiou, M., Konstantellos, I., Tzenou, T., Kopsaftopoulou, A., Liga, M., Violaki, V., Kyriazopoulou, L., Gkirkas, K., Papalexandri, A., Plata, E., Michalis, E., Leonidopoulou, T., Garofalaki, M., Sioni, A., Tziotziou, I., Lalayanni, C., Kiousiafes, D., Vassilakopoulos, T. P., ... Tsirigotis, P. (2025). The Prognostic Impact of Additional Molecular and Cytogenetic Abnormalities on AML Patients with NPM1- and/or FLT3-ITD Mutations Receiving Intensive Chemotherapy: Real-World Data from the Greek Registry. Cancers, 17(4), 667. https://doi.org/10.3390/cancers17040667